Abstract:IntroductionChronic liver diseases (CLD) are common and may lead to fibrosis, cirrhosis, and hepatic malignancy.Detection and staging of liver fibrosis is crucial for management of patients with CLD.At present, liver biopsy is the standard method for staging fibrosis, but biopsies are poorly tolerated because they are invasive and associated with some discomfort and complications.In addition, limitations of biopsy include intra-and inter-observer variation and sampling error 1,2 .In recent years, a great interest and many studies have been dedicated to the development of noninvasive tests to substitute liver biopsy for fibrosis assessment and follow-up.Unfortunately, all of them have limitations and pitfalls.To discuss their advantages and deficiencies will be helpful in scientific research and clinical practice. Invasive measurements Liver biopsyLiver biopsy has been considered as the gold standard to confirm the clinical diagnosis, to assess the severity of necro-inflammation and fibrosis, to identify cofactors and comorbidities, and to monitor the efficacy of treatments since the first liver biopsy was performed by Paul Ehrlich in 1883 3 .The procedure is particularly useful for diagnosing the earlier stages of fibrosis and identifying patients at high risk of progressing fibrosis, but it has also a number of limitations.The patient acceptance is pretty low because biopsy is expensive, invasive and associated with some discomfort and complications.Pain appears in about one fourth of patients, other complications including bleeding, biliary peritonitis, pneumothorax and a mortality rate about 0.01% 4 .Sampling error of at least 24% is reported usually because of specimen fragmentation or inadequate length.Colloredo et al concluded that an optimum specimen should be at least 20 mm in length with 11 complete portal tracts 1 .Even with adequate-sized biopsies, the interpretation might be unreliable, because the distribution of necro-inflammation and fibrosis is not homogeneous, and liver biopsy samples only 1:50 000th of the mass of the liver.Several semi-quantitative scoring systems have been proposed to describe and quantify the necro-inflammation, steatosis and fibrosis in the liver, particularly for chronic viral hepatitis.These include the Knodell histological activity index (HAI) first proposed in 1981, then modified to the Scheuer system, the METAVIR system and the Ishak modified HAI 5 .However, all the scoring systems could only provide qualitative descriptors to stage fibrosis, www.intechopen.comLiver Biopsy 252 and the staging of certain histopathological changes differ in different systems (Table 1).This could cause considerable intra-and inter-observer variation and difficulty in comparison 2 .

Advancements of non‐invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Advances of Noninvasive Methods in Diagnosis of Hepatic Fibrosis

Non-invasive in vivo Imaging Grading of Liver Fibrosis

The imaging study and progress of liver fibrosis should be emphasized

Research Progress of Non-Invasive Diagnosis of Liver Fibrosis

Noninvasive staging of liver fibrosis: review of current quantitative CT and MRI-based techniques

Recent Advances of Nanomaterials in Imaging Liver Fibrosis

Present situation on non-invasive assessment of liver fibrosis/cirrhosis

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Conventional and Artificial Intelligence-Based Computed Tomography and Magnetic Resonance Imaging Quantitative Techniques for Non-Invasive Liver Fibrosis Staging

Progress in Noninvasive Diagnosis of Liver Fibrosis in Patients

[Advances in Evaluations of Liver Fibrosis Using Imaging Findings].

Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives

Noninvasive Alternatives for the Assessment of Liver Fibrosis

Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease

Advances on Nanomedicines for Diagnosis and Theranostics of Hepatic Fibrosis

[Functional MR Study of Hepatic Fibrosis].

Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis

Non-invasive evaluation of liver steatosis with imaging modalities: New techniques and applications

Assessment of Fibrosis in Chronic Liver Diseases